Algernon Pharmaceuticals, a Canadian clinical stage drugmaker which has collaborated with Zhejiang Ausun Pharmaceutics of China to manufacture and supply its repurposed drug candidate NP-251 (Repirinast), has  launched a  new chronic kidney disease (CKD) research programme. As part of the new research, Algernon will investigate Repirinast use in acute interstitial nephritis as it showed a modest improvement in combination with telmisartan in lowering blood pressure.